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ABSTRACT
Several chemo-resistance mechanisms including the Bcl-2 protein family 
overexpression and constitutive activation of the PI3K/Akt/mTOR signaling have 
been documented in acute lymphoblastic leukemia (ALL), encouraging targeted 
approaches to circumvent this clinical problem. Here we analyzed the activity of 
the BH3 mimetic ABT-737 in ALL, exploring the synergistic effects with the mTOR 
inhibitor CCI-779 on ABT-737 resistant cells.We showed that a low Mcl-1/Bcl-2 plus 
Bcl-xL protein ratio determined ABT-737 responsiveness. ABT-737 exposure further 
decreased Mcl-1, inducing apoptosis on sensitive models and primary samples, while 
not affecting resistant cells. Co-inhibition of Bcl-2 and the mTOR pathway resulted 
cytotoxic on ABT-737 resistant models, by downregulating mTORC1 activity and Mcl-1 
in a proteasome-independent manner. Although Mcl-1 seemed to be critical, ectopic 
modulation did not correlate with apoptosis changes. Importantly, dual targeting 
proved effective on ABT-737 resistant samples, showing additive/synergistic effects. 
Together, our results show the efficacy of BH3 mimetics as single agent in the 
majority of the ALL samples and demonstrate that resistance to ABT-737 mostly 
correlated with Mcl-1 overexpression. Co-targeting of the Bcl-2 protein family and 
mTOR pathway enhanced drug-induced cytotoxicity by suppressing Mcl-1, providing 
a novel therapeutic approach to overcome BH3 mimetics resistance in ALL.
INTRODUCTION
Although treatment of pediatric and Philadelphia-
positive ALL patients has shown continuous progress, 
adult patients, especially those characterized by 
unfavorable prognostic factors, still present high rates of 
relapse and develop chemo-resistance during the course 
of the disease, failing to achieve further remissions and 
ultimately dying [1, 2].
Overexpression of the anti-apoptotic Bcl-2 
family proteins is commonly observed in hematological 
malignancies, including ALL. By blocking apoptosis 
induction, Bcl-2 allows leukemic cell to survive and 
proliferate irrespective of death signals that physiologically 
avoid oncogenesis transformation [3–6]. Anti-apoptotic 
members perform their activity by binding and sequestering 
Bax and Bak, thus preventing mitochondria interaction 
[7, 8]. An imbalanced expression of pro- and anti-apoptotic 
Oncotarget32090www.impactjournals.com/oncotarget
proteins has been documented in ALL [9] and Bax/Bcl-2 
ratio has been inversely correlated to prognosis as it becomes 
significantly lower at relapse [10]. Moreover, increased 
expression of Bcl-2 related proteins, frequently observed 
at diagnosis, is associated with decreased responsiveness 
to chemotherapy induction and treatment refractoriness 
[11–14]. Therefore, strategies to inhibit Bcl-2 family proteins 
have been extensively investigated over the years [15–17] 
showing high in vitro and in vivo efficacy.
ABT-737 is a small BH3 mimetic Bcl-2/Bcl-xL 
inhibitor that has demonstrated impressive pre-clinical 
activity as single agent against a wide range of solid tumors 
and hematological malignancies [14, 17–21]. In addition, 
ABT-737 strongly synergized with chemotherapeutic drugs, 
supporting its inclusion in the ALL agent armamentarium 
[22, 23]. However, although ABT-737 potently binds to 
Bcl-2, Bcl-xL and Bcl-w, it weakly interacts with Bfl-
1/A1 or Mcl-1 [16, 24]. It has been reported that high 
expression of Mcl-1 significantly reduced ABT-737 
cytotoxicity in several cancers, including ALL [25–28]. 
Moreover, cells that are initially sensitive to ABT-737 may 
become resistant by upregulating Mcl-1 at transcriptional 
or post-translational levels [28, 29]. Consistently, ectopic 
or pharmacological modulation of Mcl-1 protein levels 
restored sensitivity to ABT-737 [30, 31], thus indicating 
Mcl-1 as an important determinant for ABT-737-induced 
cytotoxicity.
In addition to major cytogenetic alterations, genomic 
or expression profiling has recently identified the activation 
of several signal transduction pathways, including 
phosphoinositide 3-kinase (PI3K)/Akt/mammalian target 
of rapamycin (mTOR), Ras/Raf/MEK/Erk, Jak/STAT and 
others as driving features of leukemia [32–34]. mTOR 
signaling is one of the most frequently dysregulated 
pathway in ALL and negatively affects patients outcome 
[35–37]. mTOR is present in two distinct multi-protein 
complexes, mTOR complex 1 (mTORC1) and mTOR 
complex 2 (mTORC2) regulating the activity of p70S6K 
and of the eukaryotic initiation factor (eIF)4E binding 
protein-1 (4EBP1) and contributing to Akt activation 
by phosphorylating S473 residue, respectively [38–40]. 
Among its multiple functions, Akt directly influences the 
transcription of Bcl-2 family genes as well as other important 
regulators of apoptosis [36, 41]. Moreover, it has been 
demonstrated that mTOR is involved in the regulation of 
Mcl-1 stability [42–44]. Indeed, by activating Akt, mTORC2 
inhibits the Gsk-3 dependent phosphorylation of Mcl-1 
on S159 residue, blocking its degradation via proteasome 
[43, 45]. Therefore, inhibition of mTOR activity may 
disrupts the balance between pro and anti-apoptotic proteins, 
further enhancing leukemic cell death. In this context, 
selective blockade of mTOR activity by rapamycin or its 
derivatives showed to be effective in different hematological 
neoplasia [46–50]. Notably, CCI-779 (Temsirolimus), 
RAD001 (Everolimus) and the ATP-competitive mTOR 
inhibitor INK128 demonstrated anti-leukemic activity on 
ALL cell lines and primary samples [50–52].
In the present study we analyzed the effects of the 
BH3 mimetic ABT-737 on ALL cell lines and primary 
samples, exploring the potential synergistic effects with 
the mTOR inhibitor CCI-779 to overcome ABT-737 
acquired resistance. Moreover, we assessed the functional 
response of ALL cells to the agent combination prior and 
after Mcl-1 manipulation to establish its role in mediating 
ABT-737 resistance.
RESULTS
ABT-737 demonstrated anti-leukemic 
activity on ALL cells
To recapitulate ABT-737 effects on ALL, we initially 
assessed ABT-737 cytotoxicity as a single agent on 
5 human ALL cell lines, looking for a potential correlation 
between drug sensitivity and Bcl-2 family members 
expression. A dose-dependent apoptosis induction was 
observed at increasing concentrations on the MOLT-4 
and RS4;11 cell lines (IC
50
s: 198 and 2 nM, respectively) 
whereas JURKAT, CEM R and CEM S proved resistant 
(IC
50
s > 5 μM) (Fig. 1a). Western blot analysis revealed 
that Bcl-2, Bcl-xL and Mcl-1 were heterogeneously 
expressed among the cell models (Fig. 1b). Interestingly, 
resistant cell lines displayed a higher Mcl-1/Bcl-2 plus 
Bcl-xL protein ratio than sensitive models. Modulation of 
protein expression induced by ABT-737 treatment was then 
analyzed in a representative sensitive, MOLT-4, or resistant, 
CEM S, cell model. ABT-737 exposure caused the cleavage 
of Bcl-2 and the downregulation of Bcl-xL and Mcl-1 only 
in the MOLT-4 cell line, whereas their expression resulted 
not affect in the resistant CEM S model (Fig. 1c).
We next evaluated the efficacy of ABT-737 on cell 
growth and apoptosis induction in 9 ALL primary samples. 
Treatment with increasing concentrations of ABT-737 
resulted in a significant decrease of cell counts and 
induced apoptosis in a dose-dependent manner. Following 
24 h of exposure, subG
0
/G1 positive cells increased from 
17.4 ± 9.3% (vehicle) to 44.2 ± 24.6% (p < 0.01) and 
73.8 ± 25.3% (p < 0.001) at 10 and 100 nM, respectively 
(Fig. 2a). No statistically significant correlation between 
ABT-737 sensitivity and clinical features of primary 
samples (age, WBC) was found. Analysis of Bcl-2, Bcl-xL 
and Mcl-1 protein levels on 7 evaluable samples showed 
an elevated expression of Bcl-2 in all primary samples 
with heterogeneous levels of Bcl-xL and Mcl-1 
(Fig. 2a). Of note, pt #5 expressed Mcl-1 at high 
levels, similar to that of CEM S cell line. According to 
cell availability, we analyzed protein modulations in 
3 primary specimens. Our results demonstrate that ABT-
737 exposure caused the appearance of cleaved Bcl-2 
and induced the downregulation of Bcl-xL and Mcl-1 
in two sensitive ALL samples. Conversely, pt #6 showed 
unchanged levels of Bcl-2, Bcl-xL and of Mcl-1 (Fig. 2c), 
proving resistant to ABT-737 (subG
0
/G1 cells = 6% at 
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100 nM). These data overlapped with the expression 
profiles previously observed on ALL cell lines, supporting 
the idea that Mcl-1 plays a role in the ABT-737 resistance 
also in ALL primary samples.
Finally, we examined the effect of ABT-737 on 
normal CD34+ cells isolated from the bone marrow of 
a healthy volunteer showing no significant increase of 
apoptosis (Fig. 2d).
Co-targeting of the Bcl-2 family proteins and of 
the mTOR pathway exerted synergistic activity 
on resistant ALL cell lines by downregulating 
Mcl-1 expression
The existence of ABT-737 resistant models led us 
to investigate whether combined treatment might enhance 
apoptosis sensitivity. We explored a novel therapeutic 
approach based on the simultaneous inhibition of the 
Bcl-2 family proteins and the mTOR pathway activity 
with ABT-737 plus CCI-779. CCI-779 concentrations were 
chosen based on previous studies demonstrating the response 
of ALL cell lines to this inhibitor (data not shown). As shown 
in Fig. 3, neither ABT-737 nor CCI-779 as single agent 
induced significant anti-proliferative or cytotoxic effects on 
the JURKAT, CEM R and CEM S cell lines. By contrast, 
the combination of ABT-737 and CCI-779 exhibited a 
synergistic activity (CI < 0.2) on the JURKAT and CEM 
R cell lines, causing a marked cell growth inhibition and 
a significant (p < 0.01) apoptosis induction. However, 
combined treatment did not affect the viability and apoptosis 
rates of the CEM S cell line (Fig. 3). Similar results were 
obtained with two additional mTOR inhibitors (RAD001 
and INK128) (Fig. 4), thus confirming that there were not 
off-target effects implicated in our findings.
Figure 1: ABT-737 affected cell growth, induced apoptosis and modulated Bcl-2 family protein expression in ALL 
cell lines. a. MOLT-4 and CEM S cell lines were exposed to the indicated concentrations of ABT-737 or vehicle (DMSO) up to 72 h. 
Apoptosis induction (upper panels) and cell counts (lower panels) were assessed by AnnV/PI staining and Trypan blue exclusion method, 
respectively. Data are shown as mean ± SD of at least three independent experiments. IC
50
s were calculated after 72 h of exposure by 
using the CalcuSyn software. b. Basal expression of selected Bcl-2 family members was analyzed by western blotting in ALL cell lines 
(left) and quantified by densitometric analysis (right). HSP70 served as loading control. Relative amount of each protein was calculated by 
dividing the densitometric value of the protein for that of the corresponding HSP70 and then Mcl-1/Bcl-2 plus Bcl-xL ratio was assessed. 
c. Modulation of protein expression following 24 h of exposure to ABT-737 or vehicle (DMSO) in MOLT-4 and CEM S cell lines. Cleavage 
of Bcl-2 and levels of Bcl-xL and Mcl-1 were assessed by western blotting. GADPH was used as loading control. * for p < 0.05.
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Figure 2: ABT-737 induced apoptosis in ALL primary samples but not in normal CD34+ cells. a. Nine ALL primary 
samples were treated with ABT-737 or vehicle (DMSO) for 24 h. Apoptosis induction was measured by flow cytometry AO technique 
and reported as percentage of subG
0
/G1 positive cells. b. Western blot analysis of basal Bcl-2, Bcl-xL and Mcl-1 protein levels in ALL 
primary samples with available cell amounts. CEM S cell lines was used as reference. c. Modulation of protein expression following 24 h 
of exposure to ABT-737 or vehicle (DMSO) in three primary samples. Mcl-1 was not assessed in pt #3 due to low amount of protein lysate. 
GADPH served as loading control. d. Representative flow cytometric analysis of ABT-737 exposure on normal CD34+ cells. Cytotoxic 
effects were shown as percentage of AnnV+ cells.
Figure 3: ABT-737/CCI-779 combination triggered synergistic apoptosis in ABT-737 resistant ALL cell lines. JURKAT, 
CEM R and CEM S were exposed up to 72 h to ABT-737 and CCI-779, alone or in combination. Apoptosis induction (upper panels) and cell 
counts (lower panels) were assessed by AnnV/PI staining and Trypan blue exclusion method, respectively. Results are shown as mean ± SD 
of at least three independent experiments. CI was calculated by conservative isobologram analysis using the CalcuSyn software. CI values 
< 0.8 were considered synergistic, between 0.8 and 1.2 additive, > 1.2 antagonistic. * for p < 0.01 relative to control conditions.
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To understand the molecular mechanisms underlying 
the synergistic interaction, we incubated JURKAT, CEM R 
and CEM S cells with ABT-737 and CCI-779, alone and 
in combination, and protein lysates were obtained at 3 and 
24 h. Western blot analysis revealed that a 3 h CCI-779 
exposure, alone and in combination with ABT-737, 
induced the downregulation of the mTORC1 downstream 
targets p-p70S6K(T389) and p-4EBP1(T37/46) in JURKAT 
and CEM R cells, while no changes were observed in the 
CEM S cell line (Fig. 5a). Moreover, a prolonged exposure 
(24 h) to the inhibitors demonstrated that CCI-779, 
when used in combination with ABT-737, enhanced 
the dephosphorylation of Akt(S473) and consequently 
of Gsk3α/β(S21/9) in comparison to single treatment, 
strongly decreasing Mcl-1 expression in the JURKAT and 
CEM R cell lines. The combination failed to reduce Mcl-1 
levels in the CEM S cell line (Fig. 5b).
Proteasome is not involved in decreasing  
Mcl-1 expression
To investigate whether Mcl-1 downregulation would 
be dependent on Gsk3-induced proteasomal degradation, 
we treated the JURKAT and CEM R cell lines with the 
proteasome inhibitor MG132 prior to the addition of 
ABT-737 and CCI-779 and the expression of Mcl-1 was 
monitored at 16 h. No increase in Mcl-1 protein level was 
observed in MG132-treated cells (Fig. 5c), thus indicating 
that proteasome is not involved in Mcl-1 degradation. 
To further support that Gsk3-induced Mcl-1 degradation 
is not involved in ABT-737 resistance, we transfected 
JURKAT and CEM R cells with a Mcl-1 protein mutant 
lacking the Gsk3 phosphorylation site S159A (Mcl-1S159A) 
which is known to regulate Mcl-1 stability. An efficient 
transfection was achieved (Fig. 6a) and both cell lines, as 
expected, showed a reduction in Mcl-1 downregulation 
after treatment with ABT-737 and CCI-779, both alone 
and in combination (Fig. 6b). Unexpectedly, however, 
cytotoxicity induced by single or dual treatment was not 
reduced in Mcl-1S159A cells compared to control cell lines 
(Fig. 6c). Therefore, we hypothesized that inhibition of 
4EBP1 and subsequently of protein translation in the 
JURKAT and CEM R cell lines led to the downregulation 
of Mcl-1 expression explaining the ability of the ABT-737/
CCI-779 combination to trigger apoptosis in JURKAT and 
CEM R cells but not in the CEM S cell line (Fig. 5b).
Combined treatment failed to show synergistic 
activity where Mcl-1 is not the main 
resistant factor
Since the combination of ABT-737 and CCI-779 
resulted unable to reduce Mcl-1 expression in the CEM 
S cell line, we performed RNA interference of Mcl-1 
(Mcl-1i). Efficient silencing was achieved without any 
changes in Bcl-2 and Bcl-xL protein levels (Fig. 7a). 
We then exposed wt and Mcl-1i cells to ABT-737 and 
CCI-779, alone and in combination, demonstrating neither 
changes in protein expression nor increase of apoptosis 
in Mcl-1i CEM S cells when compared to their controls 
(Fig. 7b). Only a slight reduction in cell growth was 
noticed. We thus concluded that in this model Mcl-1 is not 
the unique determinant of ABT-737 resistance.
ABT-737 synergized with CCI-779 enhancing 
apoptosis in resistant ALL primary samples
To evaluate the effectiveness of ABT-737 and 
CCI-779 as a potential therapeutic strategy in ALL, 
18 additional primary samples were exposed to the drugs, 
alone and in combination. As before, basal expression 
levels of Bcl-2 family members was analyzed by western 
blot on 10 evaluable samples. Bcl-2 and Bcl-xL 
were heterogeneously expressed in the majority of 
samples (7/10 and 9/10, respectively) and almost all 
samples (9/10) shared the overexpression of Mcl-1 
Figure 4: ABT-737 plus RAD001 or INK128 combination confirmed the effectiveness of Bcl-2/mTOR inhibition in 
ABT-737 resistant ALL cell lines. JURKAT, CEM R and CEM S were exposed up to 72 h to ABT-737, CCI-779, RAD001 and 
INK128, alone or in combination. The concentrations were chosen based on previous studies demonstrating the response of ALL cell 
lines to these inhibitors. Apoptosis induction was assessed by AnnV/PI staining. Results are shown as mean ± SD of three independent 
experiments. * for p < 0.05 relative to control conditions.
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when compared to NPBLs (Fig. 8a). CCI-779 treatment 
as a single agent demonstrated a modest apoptosis 
activity (increase of subG
0
/G1 peak from 19.9 ± 11.6% 
(vehicle) to 23.8 ± 15.6% at 5000 nM). By contrast, 
ABT-737 confirmed its cytotoxic effects also on these 
samples, inducing a significant (p < 0.001) apoptosis 
induction from 19.9% ± 11.6 (vehicle) to 69.9% ± 21.0 
at 50 nM. Importantly, ABT-737 activity was observed 
in the majority of samples (15/18) while the remaining 
3 specimens exhibited less than 20% of net apoptosis 
(Fig. 8b). Nevertheless, combined treatment was able to 
induce synergistic (pt #10, #26) or additive (pt #17) pro-
apoptotic effects on these 3 samples (Fig. 8b, arrows). No 
significant differences in sensitivity to ABT-737 as single 
agent or in combination with CCI-779 were observed when 
data were sorted by age and/or WBC (data not shown). 
Further analysis of correlation between ABT-737/CCI-779 
sensitivity and protein expression in these three resistant 
samples revealed that pt #17, which displayed additive 
effects in combination, was characterized by negligible 
levels of Bcl-2 and Bcl-xL with high expression of Mcl-1, 
thus supporting the lower ABT-737 activity as single agent 
and in combination. Conversely, pt #10 and #26, which 
displayed elevated protein levels of Bcl-2, Bcl-xL and 
Mcl-1, showed a synergistic apoptosis induction associated 
with a marked downregulation of p-4EBP1(T37/46) and 
Mcl-1 (Fig. 8c), thus resembling the molecular changes 
previously observed in the JURKAT and CEM R cell lines.
Discussion
Over the last years, attention in ALL has been 
focused on the molecular mechanisms underlying drug 
resistance, developing novel strategies to modulate 
aberrant signaling rising from acquired lesions [53]. 
Among these, therapeutic targeting of the deregulated 
apoptotic machinery represents an attractive area of 
investigation [54, 55]. Anti-apoptotic Bcl-2 related 
proteins allow leukemic survival and cell proliferation 
by interfering with the intrinsic pathway of apoptosis. 
Thus, inhibition of Bcl-2 family members represents a 
highly potent stimulus to trigger apoptosis in leukemic 
cells. ABT-737 is a small-molecule inhibitor of Bcl-2, 
Bcl-xL and Bcl-w that has been investigated in several 
human cancers, including hematological neoplasias. 
Here we first evaluated the activity of ABT-737 as single 
agent on ALL cell lines and primary samples, assessing 
the correlation between Bcl-2 family member expression 
Figure 5: Effects of ABT-737/CCI-779 combination on Bcl-2 and PI3K/Akt/mTOR pathway in ALL cell lines. ABT-737 
resistant cell lines were cultured in the presence of ABT-737 (1000 nM for JURKAT and CEM R, 5000 nM for CEM S), CCI-779 (1000 nM 
for JURKAT, 5000 nM for CEM R and CEM S) or their combination and the expression of selected PI3K/Akt/mTOR pathway components 
and Bcl-2 family members was analyzed by western blot after 3 h a. and 24 h b. of exposure. Representative immunoblots are shown. 
c. JURKAT cell line was incubated with or without 3 μM MG132 and then exposed to ABT-737 (1000 nM), CCI-779 (1000 nM) and their 
combination. Mcl-1 expression was assessed at 16 h by western blot analysis. Results are representative of three independent experiments. 
HSP70 and GADPH were used as loading control.
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and ABT-737 sensitivity. Previous reports showed that 
high Bcl-2 or low Mcl-1 expression correlate with 
in vitro sensitivity of several cancer cell lines to ABT-737 
[24, 27, 56]. Consistently, Bcl-2 protein expression was 
associated with drug efficacy in acute myeloid leukemia 
(AML) [25]. However, in ALL, Bcl-2 dependence rather 
than basal expression seemed to have a greater impact 
on cellular response [14]. Indeed, Kang and colleagues 
[57] showed that levels of anti-apoptotic Bcl-2 family 
members are not associated with ALL susceptibility to 
ABT-737. More recently, it has been demonstrated that 
Mcl-1, Noxa and Bim protein levels significantly impact 
on in vitro resistance of ALL cell lines. By contrast, 
only Bim rather than Bax, Bak or increased Mcl-1 
expression determined in vivo sensitivity to ABT-737 
in a panel of ALL xenografts from pediatric patients 
[23]. Therefore, ABT-737 sensitivity in ALL seems to 
depend on several factors. We found that Mcl-1/Bcl-2 
plus Bcl-xL expression ratios determined ALL cell lines 
in vitro response to ABT-737. Indeed, our sensitive cell 
models were characterized by lower Mcl-1 and upper 
Bcl-2 plus Bcl-xL protein expression than resistant cell 
lines. However, it is likely that different factors (e.g. Bim) 
other than the proteins assessed in this study may affect 
ABT-737 in vitro responsiveness. In agreement with 
published data [57, 58], we demonstrated that increasing 
concentrations of ABT-737 further decreased Bcl-xL and 
Mcl-1 expression only in MOLT-4, a sensitive cell line, 
Figure 6: Mcl-1 downregulation is not dependent on proteasomal activity. JURKAT and CEM R cell lines were transfected 
with the Mcl-1 mutant S159A (Mcl-1S159A) and the effects on Mcl-1 protein expression and apoptosis induction were analyzed by western 
blot and AnnV/PI staining, respectively. a. Representative RT-PCR (left panels) and western blot analysis (right panels) after transfection 
in JURKAT and CEM R cell lines. Expression of 28S and HSP70 were used as internal controls. b. CEM R cell line was treated with 
vehicle (DMSO) or ABT-737 (1000 nM) and CCI-779 (5000 nM), alone and in combination. Mcl-1 protein expression was analyzed by 
western blot after 24 h of exposure. Results from one of at least three independent experiments are shown. HSP70 served as loading control. 
c. Analysis of drug-induced apoptosis in wt and Mcl-1S159A-transfected JURKAT and CEM R cell lines after exposure to the indicated 
concentrations. No statistically significant differences were found between wt and Mcl-1S159A-transfected JURKAT and CEM R cells after 
treatment with ABT-737 as single agent or in combination.
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Figure 7: Knockdown of Mcl-1 expression in CEM S cell line failed to enhance drug-induced apoptosis. a. Analysis of 
Mcl-1 level (upper panel) and of modulation of Bcl-2 family members protein expression (lower panel) in wt or Mcl-1i CEM S cells prior 
and after exposure to ABT-737 (5000 nM) and CCI-779 (5000 nM), alone or in combination. Representative immunoblots from one of three 
independent experiments are shown. Tubulin was used as loading control. b. CEM S cell line was treated up to 72 h with vehicle (DMSO) 
or ABT-737 and CCI-779, alone or in combination. The effects on cell growth (lower panels) and apoptosis induction (upper panels) were 
analyzed at the indicated times by Trypan blue exclusion method and AnnV/PI staining, respectively. Results are presented as mean ± SD of 
at least three different experiments. No statistically significant differences were found between wt and Mcl-1i CEM S cells after treatment 
with ABT-737 as single agent or in combination.
Figure 8: ABT-737 plus CCI-779 combination triggered apoptosis in resistant ALL primary cells. a. Analysis of 
basal expression of Bcl-2, Bcl-xL and Mcl-1 in 10 evaluable ALL primary samples. NPBLs, MOLT-4 and CEM R cell lines were used 
as references. GAPDH served as loading control. b. Freshly isolated leukemic blasts from 18 ALL patients were seeded at a density 
of 1 × 106/mL and treated for 24 h with ABT-737 (50 nM) and CCI-779 (5000 nM), alone or in combination. Apoptosis induction was 
determined by AO technique. Results are reported as percentage of subG
0
/G1 positive cells for individual patient. Synergistic or additive 
interaction were indicated by black arrows. c. Leukemic blasts from sample #10 and #26 were exposed for 24 h to ABT-737, CCI-779 or 
their combination. Apoptosis induction and protein expression were assessed by AnnV/PI staining and western blot analysis, respectively.
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inducing significant cell growth reduction and apoptosis 
at nanomolar concentration. By contrast, protein levels 
were not affected in CEM S cells, a resistant cell model, 
showing no significant changes of apoptosis induction 
even at micromolar doses. Cytotoxic efficacy of ABT-737 
was then confirmed on ALL primary samples, with the 
majority of specimens demonstrating significant apoptosis 
induction when compared to their controls. By contrast, 
normal CD34+ cells were remarkably resistant to ABT-
737, as already shown by Konopleva et al. [25],
Interestingly, we found a resistant primary sample 
in which Mcl-1 expression was not affected by ABT-
737 exposure. Conversely, analysis of two sensitive 
ALL samples revealed a marked Mcl-1 downregulation 
following ABT-737 exposure, likely due to apoptosis 
induction. These results, in accordance to published data 
[56], support the contribution of Mcl-1 downregulation in 
the ABT-737-induced cytotoxicity.
To overcome BH3 mimetics resistance, we explored 
a novel therapeutic approach by using the mTOR inhibitor 
CCI-779 in ALL cell lines and primary samples. The 
PI3K/mTOR pathway is frequently found constitutively 
activated in ALL [35, 36, 59] and targeted inhibition 
of mTOR, alone or in association with PI3K, has been 
investigated at multiple levels, generally displaying 
better results in vitro than in vivo. Recently, it has been 
demonstrated that activated Akt may decrease ABT-737 
activity, suggesting a functional role of this signaling also 
in protecting leukemia cells from BH3 mimetic-induced 
apoptosis [60]. Consistently, simultaneous inhibition of 
the PI3K/mTOR pathway, by BEZ235, and Bcl-2/Bcl-xL, 
by ABT-737, strongly potentiated cytotoxicity of single 
agents and markedly reduced colony formation in multiple 
AML cell lines and primary blast specimens while exerted 
only modest toxicity toward normal hematopoietic 
progenitors [60]. Moreover, Jin and colleagues [61] 
showed that the combination of GDC-0941 and ABT-737 
triggered mitochondrial apoptosis in AML cells co-cultured 
with stromal cells under hypoxic conditions, thus 
suggesting the efficacy of this approach even under 
the protective conditions afforded by the bone marrow 
microenvironment. It has also been demonstrated that 
PI3K/mTOR signaling contributed to ABT-737 resistance 
in Burkitt lymphoma cells, and their inhibition through 
dual or active site mTOR inhibitors induced synergistic 
caspase activation, rendering chemoresistant cells 
sensitive to apoptosis induction [62]. In addition, data 
obtained on different solid tumors [31, 63, 64] showed that 
blockade of mTOR signaling and Bcl-2 activity triggered 
massive in vitro apoptosis by loss of mitochondrial 
membrane potential, activation of caspases and Mcl-
1 downregulation and was highly synergistic in vivo 
providing tumor regressions without notable hematologic 
suppression. Since numerous of the aforementioned 
inhibitors have shown promising results in different 
stages of clinical trials, alone or in combination with 
chemotherapy [clinicaltrials.gov], it has been proposed 
that the simultaneous inhibition of the mTOR pathway 
and Bcl-2 activity in cancer cells, even in those resistant 
to single agents, may have important clinical implications. 
We found that CCI-779, RAD001 and INK128, as single 
agents, modestly impaired resistant cell line proliferation, 
resulting in a no significant pro-apoptotic activity. By 
contrast, co-targeting of Bcl-2 and mTOR activity with all 
the above inhibitors strongly sensitized resistant JURKAT 
and CEM R cell lines to apoptosis, thus reverting the 
acquired ABT-737 resistance. Interestingly, since CEM 
R cells are known to be insensitive to vinblastine [65], 
we hypothesized that combined treatment can be effective 
also in other chemoresistant models even those MDR1-
related. However, the CEM S cell line failed to show 
any apoptotic increase after exposure to all tested 
combination, suggesting an analysis of protein expression 
to better understand the biological reasons underlying 
synergistic interaction between the aforementioned drugs. 
We observed that CCI-779, especially when in combination 
with ABT-737, inhibited the mTORC1 pathway activity by 
decreasing phosphorylation levels of p70S6K and 4EBP1 
only in JURKAT and CEM R, thus reinforcing the idea 
of a context-dependent role of mTORC1 in the increased 
ABT-737-mediated cell death [31]. Moreover, after 24 h of 
treatment, CCI-779 also affected the mTORC2 pathway, 
as demonstrated by the downregulation of p-Akt(S473) 
and p-Gsk3α/β(S21/9), indicating that prolonged exposure 
to rapamycin derivative may be effective, at least in part, 
also on PI3K downstream targets. Of note, combined 
treatment markedly decreased Mcl-1 protein levels in the 
JURKAT and CEM R cell lines, while not affecting its 
expression in CEM S cells. We excluded the involvement 
of proteasomal degradation in ABT-737-induced Mcl-
1 downregulation since protein levels appeared not 
increased in cells treated with MG132, a well-known 
proteasome inhibitor, compared to their controls. We also 
transfected a mutant of Mcl-1 which lacks the S159 
residue, a known Gsk3 phosphorylation site that marks 
Mcl-1 for proteasomal degradation, in the JURKAT and 
CEM R cell lines. Although an efficient transfection was 
achieved and both cell lines showed a reduction in Mcl-1 
downregulation, we unexpectedly detected no reduction 
in apoptosis induction after single or combined treatment, 
further supporting the idea that proteasomal degradation 
is not involved in Mcl-1 degradation. These finding led us 
to hypothesize that inhibition of 4EBP1-dependent protein 
translation may be important for the synergistic interaction 
between ABT-737 and CCI-779. Further experiments are 
needed to clarify unequivocally the precise contribution of 
molecular mechanisms (e.g. caspase-dependent cleavage) 
in determining Mcl-1 levels on ALL cells.
However, our results demonstrated that in some model, 
as the CEM S cell line, Mcl-1 is not a unique determinant 
of ABT-737 resistance. Indeed, when we knocked down 
protein expression by RNA interference, we observed no 
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changes in treatment cytotoxicity, even after exposure to 
the combination. Different groups have already reported 
that, in certain contexts, Mcl-1 downregulation although 
required is incapable itself of initiating apoptosis [66, 67]. 
In addition, loss of Bim, combined absence of Bax and Bak 
or overexpression of Bcl-xL and Bcl-w have been shown to 
make lymphoma cells resistant to ABT-737 in vitro and in 
vivo, even in the absence of endogenous Mcl-1 [68], thus 
indicating that targeting of more than one antiapoptotic 
protein may be required for the full engagement of the 
apoptotic machinery. Therefore, we concluded that Mcl-1 
downregulation likely cooperates with other independent 
mechanisms to support ABT-737 resistance in ALL.
The effectiveness of the ABT-737 and CCI-779 
combination as a novel therapeutic strategy was further 
evaluated on additional primary ALL samples. CCI-779 
treatment as monotherapy demonstrated only a modest 
apoptosis activity on these samples, whereas ABT-737 
confirmed its cytotoxic effects inducing significant apoptosis 
increase on the large majority of samples. Importantly, 
combined treatment was able to sensitize ABT-737 
resistant samples to apoptosis in an additive or synergistic 
fashion, thus overcoming the acquired resistance to ABT-
737. Of note, analysis of protein expression revealed that 
samples that displayed additive effects in combination were 
characterized by negligible levels of Bcl-2 and Bcl-xL with 
high expression of Mcl-1, supporting lower drug activities. 
Conversely, the other ABT-737 resistant samples displayed 
elevated protein levels of Bcl-2, Bcl-xL and Mcl-1, showing 
a synergistic apoptosis induction after combined treatment 
associated with a marked downregulation of Mcl-1. 
However we cannot exclude the existence of primary 
samples that exhibit a resistance phenotype as the CEM S 
cell line (i.e. not dependent only from Mcl-1).
In conclusion, our study show the efficacy of BH3 
mimetics as single agent in the majority of the ALL 
samples and demonstrate that Mcl-1 represents the main 
resistance factor to the BH3 mimetic ABT-737 in ALL 
cell lines and primary samples. Co-targeting of the Bcl-2 
family proteins and mTOR pathway effectively enhanced 
single drug cytotoxicity by downregulating mTORC1 
activity and Mcl-1 expression. Additional resistant 
mechanisms, however, should be taken into account 
since, in certain ALL models, Mcl-1 modulation failed to 
overcome by itself ABT-737 resistance, thus suggesting 
the existence of other mechanisms of resistance to BH3 
mimetics.
MATERIALS AND METHODS
Primary samples, cells cultures and in vitro 
treatments
Bone marrow or peripheral blood primary samples 
from 14 adult and 13 pediatric ALL patients (Table 1) 
were collected after informed consent in accordance with 
the Helsinki Declaration and approved by the Institutional 
Review Board of the Sapienza University of Rome and 
normal peripheral blood lymphocytes (NPBLs) were 
purified by Ficoll-Hypaque (Sigma-Aldrich, MO, USA) 
density-gradient centrifugation. Only specimens with 
blast counts > 70% were included in this study. For 
in vitro treatments, ABT-737 (kindly provided by Abbott 
Laboratories) and CCI-779 (Novartis, Basel, Switzerland) 
were prepared in DMSO and ethanol to a stock 
concentration of 10 and 20 mM, respectively. RAD001 
(Sigma-Aldrich) and INK128 (Selleckchem, Germany) 
were both diluted in DMSO to a stock concentration of 
10 mM. ALL cell lines (MOLT4, RS4;11, JURKAT, 
CEM R and CEM S) were cultured in RPMI 1640 medium 
(Euroclone, Milan, Italy) containing 10% heat inactivated 
fetal bovine serum, 2 mM l-glutamine and antibiotics 
at 37°C under 5% CO2 - 95% air and harvested in log-
phase growth. For each experiment, cell lines and primary 
samples were plated at concentration of 0.2 × 106/mL 
and 1 × 106/mL, respectively. Viability was assessed by 
triplicate Trypan blue exclusion counting. To establish 
the optimal concentration for drug treatment, MTT 
[3–4,5-dimethylthythiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] assays (Sigma-Aldrich) were performed. Cell 
lines and primary samples were incubated up to 72 h with 
ABT-737 (ranging from 10 to 5000 nM), CCI-779 (10 to 
20000 nM), RAD001 (500 to 10000 nM) and INK128 
(1 to 500 nM) alone and in combination. For proteasome 
inhibition, 3 μM of MG-132 (Sigma-Aldrich) was added 
to the medium 3 h before drugs administration.
Apoptosis and cell-cycle analysis
Cell cycle analysis was performed by Acridine 
Orange technique, as previously described [69]. To 
evaluate apoptosis levels, cells were examined over a 
culture period of 24–72 h using Annexin V-fluorescein 
isothiocyanate (FITC)/propidium iodide (PI) staining, as 
previously described [70]. Apoptosis induction was further 
measured by evaluating the subG
0
/G1 peak using AO 
technique, as described [71]. Flow cytometric analyses 
were carried out using both FACSCan and Accuri C6 flow 
cytometer (BD Biosciences, CA, USA). Cytotoxic activity 
induced by in vitro treatments was evaluate by measuring 
the net apoptosis rate obtained from the difference between 
subG
0
/G1 value of each condition and of that of controls.
Western blot analysis
Protein expression of Bcl-2 family and PI3K/
Akt/mTOR pathway key components of ALL cell lines 
and primary samples with available amount of cells 
was analyzed by western blotting. Cells were exposed 
to ABT-737 and CCI-779 and lysed in ice-solution 
containing 10 mM NaF, 1 mM Na3VO4, 150 mM 
NaCl, 1 mM MgCl2, 1 mM CaCl2, 0.1% NaN3, 10 mM 
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iodoacetamide, 3 mM PMSF and 1% Triton X-100 
(Sigma-Aldrich) supplemented with protease inhibitor 
cocktail (Roche Diagnostics, Indianapolis, USA). Equal 
amounts of proteins were subjected to SDS–PAGE. After 
electrotransfer on nitrocellulose (Bio-Rad Laboratories, 
CA, USA), membranes were blocked in 5% w/v non-fat 
dry milk and incubated overnight with primary antibodies, 
according to manufacturer’s instruction. Blots were then 
probed with HRP-conjugated secondary antibodies for 1 
h at room temperature and developed using ECL reagent. 
Resulting signals were collected on x-ray films, digitally 
scanned and quantified using Image J software (NIH, 
Bethesda, MD, USA).
The antibodies used for Western blot were as 
follows: anti Bcl-2 (DAKO Corp, Carpinteria, CA, USA), 
anti Mcl-1 (Santa Cruz Biotechnology, CA, USA), all the 
others antibodies were purchased from Cell Signaling 
Technology (Beverly, Massachusetts, USA).
Transfection
Electroporation was performed by Bio-Rad Gen-
Pulser II apparatus (Bio-Rad). JURKAT cells were 
counted, centrifuged and resuspended in PBS (Euroclone). 
Four hundred microliters of cell suspension (6 × 106 
cells) was mixed with 20 μg pcDNA3.1-hMcl-1(S159A) 
Table 1: Clinical and biological features of ALL primary samples included in this study.
# Type of ALL Sex Age WBC (103/ml) Blasts Cytogenetics & molecular alterations
1 B-ALL m adult 15,4 > 70% t(9;22)
2 B-ALL f adult 15 > 70% t(9;22)
3 B-ALL common f adult 82,7 88% t(9;22)
4 B-ALL common m pediatric 123,5 83% t(9;22)
5 B-ALL f adult 22,4 100% t(4;11)
6 B-ALL m pediatric 69,5 85% mol neg
7 B-ALL m adult 232 92% t(4;11)
8 B-ALL common f adult 41,2 100% t(9;22), t(q34,p11)
9 B-ALL m pediatric 20,7 87% t(11;19)
10 T-ALL m adult 470 92% 46 XY, t(7;11)(q33,p15) [8], idem del6(q13,q21)
11 B-ALL common f pediatric 26,1 80% mol neg
12 B-ALL common f pediatric 7 > 70% 49 XXX, +8, +21 [2]/46 XX [19], t(12;21)
13 B-ALL common f pediatric 42,8 88% mol neg
14 T-ALL m adult 28 70% 46 XY, mol neg
15 Lymphoma leuk m adult 92 80% mol neg
16 B-ALL common f pediatric 3,7 > 70% mol neg
17 mature B-ALL f pediatric 13,1 86% t(8;14)
18 T-ALL m adult 22 80% mol neg
19 B-ALL m adult 9 96% mol neg
20 B-ALL f adult 321 97% t(9;22)
21 B-ALL common m pediatric 173,1 91% na
22 B-ALL common m pediatric 103 94% t(12;21)
23 Lymphoma leuk m adult 55,4 84% t(11;19)(q32,q13)
24 T-ALL m pediatric 361,5 98% na
25 B-ALL common m pediatric 99,1 88% na
26 B-ALL f adult 2,2 90% na
27 B-ALL m pediatric 345,4 98% t(4;11)
Abbreviations: mol neg, molecular negative; na, not assessed
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(Addgene plasmid 25374). Cells were electroporated 
in a 4-mm cuvette at 310V, 975μF. CEM R cells were 
counted, centrifuged and resuspended in PBS. Four 
hundred microliters of cell suspension (4 × 106 cells) 
was mixed with 20 μg of pcDNA3.1-hMcl-1(S159A). 
Cells were electroporated in a 4-mm cuvette (Bio-Rad) 
at 250 V, 950 μF. Cells were stored on ice for 10 min and 
then gently transferred to 15 ml of culture media. Stable 
transfectants were selected in medium containing G418 
(Invitrogen, Milan, Italy) for fifteen days.
Plasmids and Infection
Each lentiviral shRNA construct, previously described 
[25], was transfected into 293T cells using Lipofectamine 
2000 (Invitrogen). Following 72 h post-transfection, virus-
containing supernatants were collected and used to infect 
cells by the spin-inoculation method. Briefly, 2 × 106 cells 
were added with 2 ml of virus and 8 μg/mL polybrene, 
transferred in a multiwell plate and then centrifuged at 1500 
g for 90 minutes at 30°C. Once the cells have entered log 
phase, selection was applied to obtain stable clones.
Statistical analysis
All data were obtained from at least three independent 
experiments and are presented as means ± SD (standard 
deviation). Significant differences between experimental 
values was determined by using the Student’s t test. For 
combination experiments, analysis of synergism was 
assessed by using the Chou-Talalay method and the 
CalcuSyn software (Biosoft, Cambridge, MA, USA). CI 
values lower than 0.8 were considered synergistic, between 
0.8 and 1.2 additive, and greater than 1.2 antagonistic.
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